These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 1716649

  • 1. Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro.
    Johnson VA, Merrill DP, Videler JA, Chou TC, Byington RE, Eron JJ, D'Aquila RT, Hirsch MS.
    J Infect Dis; 1991 Oct; 164(4):646-55. PubMed ID: 1716649
    [Abstract] [Full Text] [Related]

  • 2. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.
    St Clair MH, Martin JL, Tudor-Williams G, Bach MC, Vavro CL, King DM, Kellam P, Kemp SD, Larder BA.
    Science; 1991 Sep 27; 253(5027):1557-9. PubMed ID: 1716788
    [Abstract] [Full Text] [Related]

  • 3. Response of Ethiopian human immunodeficiency virus type 1 isolates to antiviral compounds.
    Wondimu Z, Sönnerborg A, Ayehunie S, Britton S, Strannegård O.
    Antiviral Res; 1992 Oct 01; 19(4):353-9. PubMed ID: 1281393
    [Abstract] [Full Text] [Related]

  • 4. Three-drug synergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4, and recombinant interferon-alpha A.
    Johnson VA, Barlow MA, Merrill DP, Chou TC, Hirsch MS.
    J Infect Dis; 1990 Jun 01; 161(6):1059-67. PubMed ID: 2345291
    [Abstract] [Full Text] [Related]

  • 5. In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine.
    Gao Q, Gu ZX, Parniak MA, Li XG, Wainberg MA.
    J Virol; 1992 Jan 01; 66(1):12-9. PubMed ID: 1727474
    [Abstract] [Full Text] [Related]

  • 6. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group.
    Larder BA, Kohli A, Bloor S, Kemp SD, Harrigan PR, Schooley RT, Lange JM, Pennington KN, St Clair MH.
    J Virol; 1996 Sep 01; 70(9):5922-9. PubMed ID: 8709213
    [Abstract] [Full Text] [Related]

  • 7. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine.
    Gu Z, Gao Q, Li X, Parniak MA, Wainberg MA.
    J Virol; 1992 Dec 01; 66(12):7128-35. PubMed ID: 1279198
    [Abstract] [Full Text] [Related]

  • 8. pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo.
    Eron JJ, Chow YK, Caliendo AM, Videler J, Devore KM, Cooley TP, Liebman HA, Kaplan JC, Hirsch MS, D'Aquila RT.
    Antimicrob Agents Chemother; 1993 Jul 01; 37(7):1480-7. PubMed ID: 7689822
    [Abstract] [Full Text] [Related]

  • 9. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro.
    Larder BA, Kellam P, Kemp SD.
    Nature; 1993 Sep 30; 365(6445):451-3. PubMed ID: 7692302
    [Abstract] [Full Text] [Related]

  • 10. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.
    Chow YK, Hirsch MS, Merrill DP, Bechtel LJ, Eron JJ, Kaplan JC, D'Aquila RT.
    Nature; 1993 Feb 18; 361(6413):650-4. PubMed ID: 7679778
    [Abstract] [Full Text] [Related]

  • 11. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy.
    Iversen AK, Shafer RW, Wehrly K, Winters MA, Mullins JI, Chesebro B, Merigan TC.
    J Virol; 1996 Feb 18; 70(2):1086-90. PubMed ID: 8551567
    [Abstract] [Full Text] [Related]

  • 12. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.
    Shafer RW, Kozal MJ, Winters MA, Iversen AK, Katzenstein DA, Ragni MV, Meyer WA, Gupta P, Rasheed S, Coombs R.
    J Infect Dis; 1994 Apr 18; 169(4):722-9. PubMed ID: 8133086
    [Abstract] [Full Text] [Related]

  • 13. Pharmacodynamic studies (PD) of didanosine (ddI) alone and in combination with azidothymidine (AZT) in human T-cells; a stochastic biochemical approach to antiretroviral nucleoside drug combination in inhibiting HIV-reverse transcriptase (RT).
    Periclou AP, Nandy P, Avramis VI.
    In Vivo; 2000 Apr 18; 14(3):377-88. PubMed ID: 10904870
    [Abstract] [Full Text] [Related]

  • 14. Loss of synergistic response to combinations containing AZT in AZT-resistant HIV-1.
    Cox SW, Albert J, Wahlberg J, Uhlén M, Wahren B.
    AIDS Res Hum Retroviruses; 1992 Jul 18; 8(7):1229-34. PubMed ID: 1520536
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Didanosine and zidovudine resistance patterns in clinical isolates of human immunodeficiency virus type 1 as determined by a replication endpoint concentration assay.
    McLeod GX, McGrath JM, Ladd EA, Hammer SM.
    Antimicrob Agents Chemother; 1992 May 18; 36(5):920-5. PubMed ID: 1510414
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Ganciclovir antagonizes the anti-human immunodeficiency virus type 1 activity of zidovudine and didanosine in vitro.
    Medina DJ, Hsiung GD, Mellors JW.
    Antimicrob Agents Chemother; 1992 May 18; 36(5):1127-30. PubMed ID: 1510405
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.